Aura Health (CSE:BUZZ) CEO Daniel Cohen joined the Investing News Network at the Extraordinary Future Conference in Vancouver to discuss his company’s progress in the European cannabis market, including the German medical cannabis market.

Aura Health owns an 80 percent interest in Germany cannabis company Pharmadrug. The company is an importer, distributor, and exporter of cannabis for medical purposes. A large portion of the cannabis in Germany at the moment is sourced in the Netherlands. According to Cohen, this presents an opportunity for Aura Health to provide new strains and products through Pharmadrug.

Through Pharmadrug, Aura Health has secured a supply agreement with My Green Fields in order to provide the German medical cannabis market with high-THC strains that have shown to be in high demand. Located in Israel, My Green Fields is a cannabis cultivator expected to operate 300,000 square feet of canopy space using advanced growing techniques. According to Cohen, the supply agreement with My Green Fields has shown the potential for Aura Health to become a leading cannabis importer in Germany.

Below is a transcript of our interview with Aura Health CEO Daniel Cohen. It has been edited for clarity and brevity.

Investing News Network: Please tell us your name, company and ticker symbol. 

Aura Health CEO Daniel Cohen: Hi. My name is Daniel Cohen and I’m the CEO of Aura Health Inc. Traded on the CSE under the ticker BUZZ, B-U-Z-Z.

INN: Please provide our investor audience with an overview of Aura Health.

DC: Aura Health is a medical cannabis company that is focused on European markets. We’re focused right now on distribution. We own 80 percent of a company in Germany called Pharmadrug. Pharmadrug is an importer, distributor, and exporter in Germany. We bought the company in May and we started receiving shipments of medical cannabis in February. We started ramping up the number of pharmacies that we deal with. You know in February we dealt with zero pharmacies, today we’re dealing with 70 pharmacies and every week the number of pharmacies that we deal with grows.

Right now, we are ramping up on the distribution of cannabis from Holland. The majority of the cannabis that is in Germany right now comes from Holland. Almost 90 percent of it. We get our fair share of it and we are distributing it. The way in which to really grow this business, and to grow with the German market, which is still in its infancy, will be to bring in product beyond the product from the Netherlands. That’s the way we will grow, we will create our own brands. Late last week we announced a large supply agreement with a company that is almost finished building a state of the art indoor facility in Israel. Israel passed its export law in January. It’s still putting the framework together. As that framework is put out over the next few months and the exports begin we will be able to help that company get set up to be able to export to Germany. That product will come in under our own brand. We’re also in advanced discussions with several Canadian licensed producers who have built their facilities to the standards that the German regulator is looking for. Once we sign onto those agreements, we will be able to start looking towards bringing the product from Canada into Germany as well.

INN: How has the company positioned Pharmadrug for success in Europe? 

DC: We are currently receiving and distributing Bedrocan products. The Bedrocan product is the product that we buy from the Netherlands. The way in which we are positioning Pharmadrug is to be able to create our own brands, to be able to ramp up supply into Germany and then after that, to start exporting out of Germany into other European countries. The Israeli supply agreement that we announced last week is the first example of that product being created and being introduced to the German market. Once we sign another of these Canadian deals, we will be able to start working on that front as well. So we are going to be positioning Pharmadrug as a brand of medical cannabis and a supplier of medical cannabis to the German markets and to other European nations.

INN: Why is the My Green Fields supply agreement a significant milestone for the company?

DC: The supplier agreement we signed is a very big milestone for Pharmadrug because it basically shows that we will be a contributor to the expansion of the German markets. Right now, the German market is still in its infancy. It’s in its infancy because it’s still young. It was only legalized from the medical perspective in 2017. So we’re only in a second or third year but however, as I said before, the majority of the product in Germany right now comes from Holland from the Bedrocan product.

The way in which we are going to be able to really differentiate Pharmadrug and make it a real player in the German market will be to bring supply from outside of the Netherlands into Germany. The deal that we did with My Green Fields shows that we’re going to be able to do that. In the first year we will be bringing 500 kilograms into Germany and then every year after that for a five year agreement we will be able to bring in up to two tonnes. That is going to be a significant amount of supply into a market that is in chronic shortage right now.

INN: Are there any upcoming trends in the European cannabis market that investors should be aware of?

DC: There are several trends happening in the German market right now. Obviously new supply is going to be entering into Germany at a larger pace in 2020. The majority of the product now is still almost all flower. The developments will be able to start to bring in oils and extracts and other types of products in the THC cannabis space and we look forward to being able to contribute to that as well. Another trend is other countries are moving towards legalization as well from a medical perspective. We saw that in France in June, the Senate passed a bill basically calling for the creation of a program for medical cannabis. Poland already has a medical cannabis framework. So we’ve seen that more and more countries are moving towards creating a medical cannabis jurisdiction. So we’re seeing the expansion of that market throughout all of Europe.

INN: What’s next for Aura Health, and how does that fit into the company’s long-term goals?

DC: So there are several things that are going to be happening to Aura over the next year, year and a half. Firstly, we’re going to be able to expand on our volumes and our revenue in Germany by ramping up the Bedrocan product, which we’re in the midst to deal right now, and taking it to the next level by adding Canadian product and Israeli product that we’ve already discussed. The other thing is, we are actually quite active in Israel. In Israel, we are about to start the development of a retail chain for medical cannabis. We have actually opened the first clinic in Israel for medical cannabis. At some point early in 2020, we’re going to open our first flagship medical cannabis pharmacy. We’re going to be able to become a major player in a market that I think is about to explode. Israel had a very limited medical cannabis framework. It took eight years to go from 0 to 30,000 patients. In April, they greatly liberalized the platform and since April you’ve gone from 30,000 patients to 52,000 patients. I think in a blink of an eye we’re going to have 200,000 to 300,000 patients in Israel and by creating a retail distribution model in Israel I think we’ll be able to profit in that. That’s a big development coming for us in 2020.


This interview is sponsored by Aura Health (CSE:BUZZ). This interview provides information which was sourced by the Investing News Network (INN) and approved by Aura Health in order to help investors learn more about the company. Aura Health is a client of INN. The company’s campaign fees pay for INN to create and update this interview.

INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.

The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with Aura Health and seek advice from a qualified investment advisor.

This interview may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, receipt of property titles, etc. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. The issuer relies upon litigation protection for forward-looking statements. Investing in companies comes with uncertainties as market values can fluctuate.

  • Company surpassed 5,600 patient prescriptions for its medical cannabis products in Colombia . Prescriptions filled increased over 450% in Q3 2020 over Q2 2020
  • Khiron declared a National Strategic Project by the Government of Colombia , simplifying and accelerating administration and processes for the Company in executing strategic projects in Colombia and for export
  • Subsequent to the quarter, the Company completed a bought deal financing on November 26, 2020 , selling 32,200,000 units at a price of $0.45 per unit for aggregate gross proceeds of $14,490,000 CAD
  • Khiron signed partnerships with 15 clinics and health centres in Colombia , extending education and sales reach further across the country
  • As a result of the Company’s Doctor Zerenia TM telehealth platform more than 25% of the Company’s medical cannabis prescriptions came from outside of Bogota , expanding geographic presence of its Colombian clinics
  • Company achieved first sales of High CBD medical cannabis through private pharmacies in Peru . Additional approval received from Peru’s drug regulatory authority for Company’s High THC cannabis, with first prescriptions anticipated in Q1 2021
  • Expanded medical cannabis E-Learning platform to UK market in partnership with Medical Cannabis Clinicians Society (“MCCS”)
  • Entered an exclusive partnership with Rappi SAS, Latin America’s largest home multi-vertical app platform to distribute the Company’s CPG product portfolio, introducing Kuida products to Rappi users across the LatAm region
  • Signed agreement to distribute the Company’s Kuida TM CBD skincare brand through pharmacy, beauty retail and online markets serving the Hong Kong territory, with first orders expected in Q4 2020
  • Prudent cash use of $5 million in Q3 2020, compared with $4 million in Q2 2020, $12 million in Q1 2020 and $10 million in Q4 2019

 Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announced today its financial results for the quarter ended September 30, 2020 . These filings are available for review on the Company’s SEDAR profile at www.sedar.com All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less